EGFR and non-small cell lung carcinoma: In the current international guidelines, platinum‐based chemotherapy alone or in combination with the angiogenesis inhibitor (Ai) bevacizumab is considered as the standard first‐line option for advanced NSCLC with EGFR ex20ins.8, 10, 11, 12